Background
Team leader: Prof Penella Woll
Improvements in the systemic therapy of advanced cancer continue to be sought through the evaluation of new agents. This is a very important part of our clinical research programme and we maintain a portfolio of studies across many tumour types assessing the activity and suitability of new agents. The majority of studies are at the phase II level of development but through collaboration with industry a number of phase I studies have recently been performed or are planned. In recent years we have begun to see the therapeutic results of a greater understanding of the biology and biochemical control of cancer. This has led to an increasing number of biologically targeted therapies in addition to the more traditional cytotoxic agents